Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05761366 | Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor | recruiting | Phase 2 | 400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06404905 | Clinical Trial of BT02 in Patients With Advanced Solid Tumors(BT02) | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Dec 27, 2024 |
| clinicaltrials |
| NCT06430658 | Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer(NEXUS-2) | recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04278287 | Chemoradiotherapy in Unresectable Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06405139 | Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06655285 | The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients | completed | — | 229 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06667622 | Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06649565 | Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy | recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06611657 | Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644352 | Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma | recruiting | N/A | 236 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06615466 | Super-Hypofractionated Partial Breast Irradiation | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06612632 | Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials | recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06215885 | Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules | unknown | — | 220 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | unknown | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06490081 | Trilaciclib Prevents Myelosuppression With Chemoradiotherapy | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06585878 | A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma | not yet recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06197581 | Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer(RADIOCOM) | recruiting | N/A | 148 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06543836 | ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544668 | A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases | unknown | — | 3,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06540937 | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06540950 | Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer | unknown | Phase 2 | 47 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06498752 | MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06540508 | Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | unknown | — | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06509490 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | unknown | N/A | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06510543 | Goal-directed Enteral Nutritional Perioperative Management(GENTLEMAN) | recruiting | N/A | 400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer | recruiting | Phase 3 | 436 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06492629 | Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06490068 | Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy | unknown | Phase 2 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490107 | Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490341 | GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06483672 | Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases(LungBrain001) | not yet recruiting | Phase 2 | 27 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06481553 | RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody | unknown | — | 480 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05542680 | Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer | completed | N/A | 134 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06084897 | Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy | recruiting | Phase 2 | 120 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT03714490 | MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer(SUNRISE) | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | recruiting | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06411457 | SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer | unknown | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06419673 | Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer | active not recruiting | Phase 2 | 240 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04207918 | A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer | completed | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | not yet recruiting | Phase 2 | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06410651 | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06408623 | Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer | unknown | Phase 2 | 48 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT06405256 | Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases | unknown | — | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05443646 | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials